anky1212
☆    

India,
2019-02-21 05:05

Posting: # 19951
Views: 330
 

 Health Canada Study reports [Regulatives / Guidelines]

Dear All,

As per Health canada guidance document, "To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered. Furthermore, the persons checking for adverse reactions and those conducting the bioanalysis of samples should not know the treatment sequence."

In this case, if adverse events is ongoing, analysis both analytical and statistical phase completed, shall we submit treatment or code in study report?

Upto which phase guidance is applicable?

After completion of statistical phase if adverse event is still ongoing, still we need to follow guidance?

Thanks
Ankur Patel
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,514 posts in 4,141 threads, 1,336 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 11:25 CEST

I have not failed 700 times. I have not failed once.
I have succeeded in proving
that those 700 ways will not work.    Thomas Alva Edison

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5